Farah Khalil

2.0k total citations
37 papers, 1.3k citations indexed

About

Farah Khalil is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Farah Khalil has authored 37 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Farah Khalil's work include Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Immunotherapy and Immune Responses (4 papers). Farah Khalil is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Immunotherapy and Immune Responses (4 papers). Farah Khalil collaborates with scholars based in United States, China and Australia. Farah Khalil's co-authors include Hatem Soliman, Scott Antonia, Domenico Coppola, Timothy J. Yeatman, James J. Mulé, Andrey Loboda, Hongyue Dai, Michael Nebozhyn, Soner Altiok and David Boulware and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Farah Khalil

36 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Farah Khalil United States 15 663 452 315 214 157 37 1.3k
Jeffrey Chun Tatt Lim Singapore 22 680 1.0× 413 0.9× 505 1.6× 183 0.9× 52 0.3× 52 1.5k
Friedrich Feuerhake Germany 21 395 0.6× 215 0.5× 433 1.4× 156 0.7× 112 0.7× 89 1.6k
Soizic Garaud Belgium 26 1.3k 2.0× 1.3k 2.9× 578 1.8× 293 1.4× 31 0.2× 64 2.4k
Yul Ri Chung South Korea 21 492 0.7× 122 0.3× 426 1.4× 133 0.6× 57 0.4× 48 1.1k
Mariaelena Capone Italy 23 1.4k 2.0× 728 1.6× 1.0k 3.2× 253 1.2× 28 0.2× 68 2.2k
Victoria Bingham United Kingdom 22 430 0.6× 122 0.3× 581 1.8× 163 0.8× 62 0.4× 46 1.4k
Chang‐Jiun Wu United States 15 700 1.1× 375 0.8× 599 1.9× 221 1.0× 32 0.2× 30 1.4k
Sasha E. Stanton United States 15 1.1k 1.7× 596 1.3× 530 1.7× 274 1.3× 29 0.2× 36 1.7k
Bingliang Chen China 17 385 0.6× 281 0.6× 524 1.7× 114 0.5× 53 0.3× 47 1.1k

Countries citing papers authored by Farah Khalil

Since Specialization
Citations

This map shows the geographic impact of Farah Khalil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farah Khalil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farah Khalil more than expected).

Fields of papers citing papers by Farah Khalil

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Farah Khalil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farah Khalil. The network helps show where Farah Khalil may publish in the future.

Co-authorship network of co-authors of Farah Khalil

This figure shows the co-authorship network connecting the top 25 collaborators of Farah Khalil. A scholar is included among the top collaborators of Farah Khalil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Farah Khalil. Farah Khalil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Linsley, Drew, et al.. (2024). Deceptive learning in histopathology. Histopathology. 85(1). 116–132. 2 indexed citations
2.
Pellini, Bruna, Jiannong Li, Michael J. Schell, et al.. (2024). A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC).. Journal of Clinical Oncology. 42(16_suppl). 8545–8545. 1 indexed citations
3.
Baron, Jason M., et al.. (2024). Real-World Biomarker Test Ordering Practices in Non–Small Cell Lung Cancer: Interphysician Variation and Association With Clinical Outcomes. JCO Precision Oncology. 8(8). e2400039–e2400039. 2 indexed citations
4.
Kerr, Keith M., Lukas Bubendorf, Fernando López‐Ríos, et al.. (2023). Optimizing tissue stewardship in non‐small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists. Histopathology. 84(3). 429–439. 8 indexed citations
5.
Đačić, Sanja, William D. Travis, Jennifer M. Giltnane, et al.. (2021). Artificial intelligence (AI)–powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with non-small cell lung cancer: Results from the LCMC3 study.. Journal of Clinical Oncology. 39(15_suppl). 106–106. 13 indexed citations
6.
Mumtaz, Hamid, et al.. (2019). Primary bronchial Ewing sarcoma. International Journal of Surgery Case Reports. 61. 230–233. 3 indexed citations
7.
Gray, Jhanelle E., Alberto Chiappori, Tawee Tanvetyanon, et al.. (2018). A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. Cancer Immunology Immunotherapy. 67(12). 1853–1862. 29 indexed citations
8.
Saltos, Andreas, Farah Khalil, Jiannong Li, et al.. (2018). Clinical associations of mucin 1 in human lung cancer and precancerous lesions. Oncotarget. 9(86). 35666–35675. 25 indexed citations
9.
Cohen, Allison S., Farah Khalil, Eric A. Welsh, et al.. (2017). Cell-surface marker discovery for lung cancer. Oncotarget. 8(69). 113373–113402. 29 indexed citations
10.
Toloza, Eric M., et al.. (2016). Extensive plastic bronchitis: etiology of a rare condition. Journal of Thoracic Disease. 8(9). E961–E965. 6 indexed citations
11.
Soliman, Hatem, Farah Khalil, & Scott Antonia. (2014). PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells. PLoS ONE. 9(2). e88557–e88557. 193 indexed citations
12.
Mediavilla-Varela, Melanie, Kimberly A. Luddy, David Noyes, et al.. (2013). Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biology & Therapy. 14(9). 860–868. 81 indexed citations
13.
Soliman, Hatem, Bhupendra Rawal, Ji‐Hyun Lee, et al.. (2013). Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunology Immunotherapy. 62(5). 829–837. 73 indexed citations
14.
Coppola, Domenico, Michael Nebozhyn, Farah Khalil, et al.. (2011). Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array Profiling. American Journal Of Pathology. 179(1). 37–45. 281 indexed citations
15.
Coppola, Domenico, Farah Khalil, Steven A. Eschrich, et al.. (2008). Down‐regulation of Bax‐interacting factor‐1 in colorectal adenocarcinoma. Cancer. 113(10). 2665–2670. 69 indexed citations
16.
Calder, Kenneth B., et al.. (2008). Immunohistochemical Expression of Survivin in Cutaneous Sebaceous Lesions. American Journal of Dermatopathology. 30(6). 545–548. 11 indexed citations
17.
Calder, Kenneth B., et al.. (2008). Bif‐1 and Bax expression in cutaneous Merkel cell carcinoma. Journal of Cutaneous Pathology. 36(1). 21–25. 7 indexed citations
18.
Khalil, Farah, et al.. (2005). Verrucous Psoriasis: A Distinctive Clinicopathologic Variant of Psoriasis. American Journal of Dermatopathology. 27(3). 204–207. 14 indexed citations
19.
Keehn, Connie A., et al.. (2004). Expression of insulin‐like growth factor‐I receptor in primary cutaneous carcinomas. Journal of Cutaneous Pathology. 31(5). 368–372. 9 indexed citations
20.
Khalil, Farah, et al.. (2004). Hamartin and tuberin immunohistochemical expression in cutaneous fibroepithelial polyps. Journal of Cutaneous Pathology. 31(5). 383–387. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey Chun Tatt Lim Breakdown of academic impact, for papers by Friedrich Feuerhake Breakdown of academic impact, for papers by Soizic Garaud Breakdown of academic impact, for papers by Yul Ri Chung Breakdown of academic impact, for papers by Mariaelena Capone Breakdown of academic impact, for papers by Victoria Bingham Breakdown of academic impact, for papers by Chang‐Jiun Wu Breakdown of academic impact, for papers by Sasha E. Stanton Breakdown of academic impact, for papers by Bingliang Chen
Rankless by CCL
2026